Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Vaxart, Inc.
  6. News
  7. Summary
    VXRT   US92243A2006

VAXART, INC.

(VXRT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Vaxart, Inc. Reports Boosting Immune Responses in Subjects Previously Vaccinated by a Vaxart Vaccine

07/29/2021 | 08:22am EDT

Vaxart, Inc. announced that it has shown for the first time in clinical trials that its oral tablet vaccine platform successfully boosted immune responses in subjects previously vaccinated with a Vaxart oral vaccine more than a year earlier. Vaxart is a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection. Vaxart's programs are based on its proprietary oral vaccine platform called VAAST. The data came from Vaxart's 12-subject Phase 1b blinded study evaluating the ability of its norovirus vaccine to boost immunogenicity. Study participants were initially vaccinated with Vaxart's oral norovirus vaccine in late 2019 and were vaccinated again between February and April 2021. All seven participants who had been?previously immunized with the oral norovirus vaccine elicited?a?similar?broad range of?immune responses?to norovirus as the five subjects that had not received a prior oral vaccine dose.?? Key metrics identified in the boosting study were as follows: Serum antibody blocking titer 50,?a surrogate neutralizing antibody measurement, increased in both previously vaccinated and unvaccinated subjects by similar amounts. Antibody?secreting B cell (ASC) responses to norovirus VP1 measured?seven days post-boost were no different than?those in subjects receiving the vaccine for the first time. Serum IgG and IgA antibody responses were significantly elevated 29 days post-boost immunization, with no difference in titer between subjects that had received a prior oral norovirus vaccine?and those who had not previously been vaccinated.


ę S&P Capital IQ 2021
All news about VAXART, INC.
08:01aVAXART : #8239;to Present at the 2021 Cantor Virtual Global Healthcare Conferenc..
PR
09/16VAXART : Entry into a Material Definitive Agreement (form 8-K/A)
AQ
09/16VAXART, INC. : Entry into a Material Definitive Agreement, Termination of a Mate..
AQ
09/07VAXART : #8239;to Present at the H.C. Wainwright 23rd Annual Global Investment C..
PR
08/23VAXART : Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D...
PU
08/23VAXART, INC. : Change in Directors or Principal Officers, Financial Statements a..
AQ
08/23Vaxart, Inc. Appoints Julie M. Cherrington to the Board of Directors
CI
08/23VAXART : Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D...
PR
08/19Vaxart, Inc. Announces the Creation of an Eight-Member Scientific and Clinica..
CI
08/11INSIDER TRENDS : 90-Days of Insider Buying at Vaxart Interrupted with Share Disp..
MT
More news
Analyst Recommendations on VAXART, INC.
More recommendations
Financials (USD)
Sales 2021 1,76 M - -
Net income 2021 -77,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -12,4x
Yield 2021 -
Capitalization 1 054 M 1 054 M -
Capi. / Sales 2021 600x
Capi. / Sales 2022 57,1x
Nbr of Employees 28
Free-Float 99,4%
Chart VAXART, INC.
Duration : Period :
Vaxart, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VAXART, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 8,41 $
Average target price 12,50 $
Spread / Average Target 48,6%
EPS Revisions
Managers and Directors
Andrei Floroiu President CEO, CFO & Director
Todd C. Davis Chairman
Sean N. Tucker Chief Scientific Officer & Senior Vice President
Richard Schwartz Senior Vice President-Technical Operations
Shaily Jaini Garg SVP-Clinical Development & Project Management
Sector and Competitors
1st jan.Capi. (M$)
VAXART, INC.47.29%1 054
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
REGENERON PHARMACEUTICALS34.93%67 775
WUXI APPTEC CO., LTD.35.75%60 418
VERTEX PHARMACEUTICALS-20.33%48 850